Notable Tuesday option activity: LRCX, BIO, CHRW
[ad_1]
Among the underlying constituents of the S&P 500 Index, we saw remarkable options trading volume today at Lam Research Corp (Symbol: LRCX), where a total of 5,732 contracts were traded up to present, representing approximately 573,200 underlying shares. This equates to approximately 44.1% of LRCX’s average daily trading volume over the past month of 1.3 million shares. Particularly high volume was seen for the $290 strike put option expiring June 16, 2023, with 301 contracts traded so far today, representing approximately 30,100 underlying LRCX shares. Below is a chart showing LRCX’s trading history over the last twelve months, with the $290 strike highlighted in orange:
Bio-Rad Laboratories Inc (Symbol: BIO) recorded options trading volume of 661 contracts, representing approximately 66,100 underlying stocks or approximately 43% of BIO’s average daily trading volume over the past month. 153,575 shares. Particularly high volume was seen for the $580 strike call option expiring on December 16, 2022, with 261 contracts traded so far today, representing approximately 26,100 underlying shares of BIO. Below is a graph showing BIO’s trading history over the last twelve months, with the $580 strike highlighted in orange:
And CH Robinson Worldwide, Inc. (Symbol: CHRW) had options trading volume of 5,679 contracts, representing approximately 567,900 underlying shares or approximately 41.7% of CHRW’s average daily trading volume during the last month, or 1.4 million shares. Particularly high volume was seen for the $95 strike put option expiring on October 21, 2022, with 3,025 contracts traded so far today, representing approximately 302,500 underlying shares of CHRW. Below is a chart showing CHRW’s trading history over the past twelve months, with the strike price of $95 highlighted in orange:
For the different expirations available for LRCX options, BIO options or CHRW options, visit StockOptionsChannel.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
[ad_2]
nasdaq